2Maria Buti,Rafael Esteban.Entecavir, FTC, L-RMAU, LdT and others[].Journal of Hepatology.2003
3Fontana RJ.Mangement of patients with decompensated HBV cirrhosis[].Seminars in Liver Disease.2003
4Hom X,Little NR,Gardner SD,et al.Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection[].Pediatric Infectious Disease.2004
5Kobayashi S,Ide T,Sata M,et al.Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers[].Journal of Hepatology.2001
6Li LL,Chun TW,Yin ML,et al.Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosuppression and chemotherapy[].Hepatology.2000
7Liaw YF,Sung JJY,Chow WC,et al.Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial[].Hepatology.2003
8Liaw YF,Leung N,Guan R,et al.Asian-pacific consensus statement on the management of chronic hepatitis B:[].An updateJ Gastroenterol Hepatol.2003
9Jonas MM,Kelley DA,Mizerski J,et al.Clinic trial of lamivudine in children with chronic hepatitis B[].The New England Journal of Medicine.2002
10Sokal EM.Drug treatment of pediatric chronic hepatitis B[].Paediatric Drugs.2002
4Ichiki Y, He XS, Shimoda S, et al. T cell immunity in hepatitis B and hepatitis C virus infection: implications for autoimmunity [ J ]. Autoimmun Rev, 2005,4(2) : 82 -952.
5Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution [ J ]. Virus Res,2007,127 (2) : 164 - 176.
